Skip to main content

Table 3 Treatment regimens analysed among the eligible studies

From: Effectiveness of current and future regimens for treating genotype 3 hepatitis C virus infection: a large-scale systematic review

Treatment regimens Treatment regimen subgroups
Containing PIB PIB + GLE
PIB + GLE + RBV
PIB + PTV/r + RBV
Containing DCV DCV + SOF
DCV + SOF + RBV
Containing GZR GZR + RZR + MK-3682
GZR + EBR + MK-3682
GZR/EBR + SOF
Containing Peg-IFN Peg-IFN + RBV
Peg-IFN + SOF + RBV
Containing LDV LDV + SOF
LDV + SOF + RBV
Containing OBV OBV + PTV/r
OBV + PTV/r + RBV
OBV + PTV/r + SOF
OBV + PTV/r + SOF + RBV
Containing SOF SOF + RBV
Containing VEL VEL100 + SOF
VEL100 + SOF + VOX
VEL100 + SOF + RBV
  1. DCV daclatasvir, EBR elbasvir, GLE glecaprevir, GZR grazoprevir, LDV ledipasvir, OBV ombitasvir, Peg-IFN pegylated interferon, PIB pibrentasvir, PTV paritaprevir, RBV ribavirin, r ritonavir, SOF sofosbuvir, RZR ruzasvir, VEL100 velpatasvir 100 mg, VOX voxilaprevir